By Doug Macron

Access Pharmaceuticals last week announced that it has begun an in-house effort to adapt its proprietary vitamin B12-based technology for therapeutic RNAi applications and potentially develop orally delivered drugs.

The technology, dubbed Cobalamin, is based on the body's natural vitamin B12 uptake mechanism, Access CEO Jeff Davis told RNAi News this week. It involves merging a polymer and active pharmaceutical ingredient to make a nanoparticle, which is then coated with the vitamin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.